Nguan Soon Tan Selected Research

PPAR-beta

3/2009	Regulation of epithelial-mesenchymal IL-1 signaling by PPARbeta/delta is essential for skin homeostasis and wound healing.
10/2007	The nuclear hormone receptor peroxisome proliferator-activated receptor beta/delta potentiates cell chemotactism, polarization, and migration.
5/2005	Genetic- or transforming growth factor-beta 1-induced changes in epidermal peroxisome proliferator-activated receptor beta/delta expression dictate wound repair kinetics.
10/2004	Essential role of Smad3 in the inhibition of inflammation-induced PPARbeta/delta expression.
8/2004	The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment.
2/2004	Peroxisome proliferator-activated receptor-beta as a target for wound healing drugs.
6/2003	The anti-apoptotic role of PPARbeta contributes to efficient skin wound healing.
1/2003	Peroxisome proliferator-activated receptor (PPAR)-beta as a target for wound healing drugs: what is possible?
10/2002	Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nguan Soon Tan Research Topics

Disease

32	Neoplasms (Cancer) 01/2022 - 01/2003
21	Wounds and Injuries (Trauma) 07/2022 - 10/2002
14	Inflammation (Inflammations) 06/2020 - 02/2004
8	Neoplasm Metastasis (Metastasis) 04/2021 - 12/2010
8	Infections 10/2019 - 03/2006
7	Spontaneous Abortion (Miscarriage) 01/2021 - 01/2015
6	Threatened Abortion 01/2020 - 01/2015
4	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2018
4	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2019
4	Obesity 01/2019 - 01/2003
3	Fibrosis (Cirrhosis) 07/2022 - 01/2018
3	Hypoxia (Hypoxemia) 01/2021 - 08/2004
3	Carcinogenesis 01/2020 - 06/2012
2	Cicatrix (Scar) 07/2022 - 01/2017
2	Melanoma (Melanoma, Malignant) 01/2022 - 12/2014
2	Disease Progression 07/2021 - 01/2021
2	Glioma (Gliomas) 01/2021 - 01/2019
2	Dyslipidemias (Dyslipidemia) 10/2019 - 01/2017
2	Type 2 Diabetes Mellitus (MODY) 10/2019 - 02/2011
2	Atherosclerosis 01/2017 - 07/2013
2	Acute-Phase Reaction 01/2017 - 12/2010
2	Insulin Resistance 06/2012 - 02/2011
2	Hepatocellular Carcinoma (Hepatoma) 05/2007 - 08/2004
1	COVID-19 01/2022
1	Fatty Liver 07/2021
1	Liver Diseases (Liver Disease) 07/2021
1	Floating-harbor syndrome 07/2021
1	Colorectal Neoplasms (Colorectal Cancer) 01/2021
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/2020
1	Melanosis (Freckles) 10/2020

Drug/Important Bio-Agent (IBA)

13	AngiopoietinsIBA 04/2021 - 10/2010
12	Proteins (Proteins, Gene)FDA Link 07/2022 - 12/2010
11	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 06/2020 - 01/2003
9	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 06/2020 - 05/2005
9	PPAR-betaIBA 03/2009 - 10/2002
8	Pharmaceutical PreparationsIBA 11/2021 - 04/2014
7	Progesterone FDA LinkGeneric 01/2021 - 01/2015
7	LipidsIBA 10/2019 - 10/2010
5	CollagenIBA 07/2022 - 04/2012
5	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 06/2012
5	IntegrinsIBA 09/2014 - 12/2010
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2017
4	Glucose (Dextrose)FDA LinkGeneric 01/2018 - 10/2010
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 04/2014
3	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2019
3	HydrogelsIBA 01/2019 - 10/2016
3	Triglycerides (Triacylglycerol)IBA 01/2017 - 12/2010
3	Fibrinogen (Factor I)FDA Link 06/2012 - 10/2011
3	PPAR alphaIBA 05/2007 - 05/2004
2	Cysteine (L-Cysteine)FDA Link 07/2022 - 01/2018
2	ChemokinesIBA 01/2022 - 01/2017
2	Cisplatin (Platino)FDA LinkGeneric 11/2021 - 10/2018
2	Biocompatible Materials (Biomaterials)IBA 01/2021 - 09/2015
2	Phosphotransferases (Kinase)IBA 01/2021 - 01/2019
2	CytokinesIBA 01/2021 - 03/2020
2	PolyaminesIBA 10/2020 - 12/2014
2	GW 501516IBA 03/2020 - 01/2015
2	Neutralizing AntibodiesIBA 01/2020 - 01/2019
2	blocking factorIBA 01/2020 - 01/2015
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 11/2017
2	AdipokinesIBA 01/2018 - 08/2004
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018 - 12/2016
2	Fatty Acids (Saturated Fatty Acids)IBA 12/2017 - 12/2010
2	CyclodextrinsIBA 10/2017 - 04/2014
2	CatalaseIBA 01/2017 - 01/2015
2	LigandsIBA 01/2017 - 02/2004
2	Conditioned Culture MediaIBA 01/2017 - 12/2014
2	Transforming Growth Factors (Transforming Growth Factor)IBA 12/2014 - 05/2005
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 09/2014 - 03/2006
2	FicolinsIBA 11/2013 - 12/2010
2	Messenger RNA (mRNA)IBA 12/2005 - 08/2004
1	Small Interfering RNA (siRNA)IBA 07/2022
1	GelatinIBA 07/2022
1	Hyaluronic Acid (Hyaluronan)IBA 07/2022
1	TyramineIBA 07/2022
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2022
1	Volatile Organic CompoundsIBA 01/2022
1	ChloridesIBA 11/2021
1	PlatinumIBA 11/2021
1	phosphine (phosphane)IBA 11/2021
1	carbeneIBA 11/2021
1	Estrogens (Estrogen)FDA Link 07/2021
1	SteroidsIBA 01/2021
1	Temozolomide (Temodar)FDA LinkGeneric 01/2021
1	Tamoxifen FDA LinkGeneric 01/2021
1	GlycosyltransferasesIBA 01/2021
1	2- (4- (3- quinolin- 6- ylmethyl- 3H- (1,2,3)triazolo(4,5- b)pyrazin- 5- yl)pyrazol- 1- yl)ethanolIBA 01/2021
1	Cholinergic Agents (Cholinergics)IBA 01/2021
1	ARQ 197IBA 01/2021
1	AlginatesIBA 01/2021
1	Hormones (Hormone)IBA 01/2021
1	Tissue Adhesives (Tissue Adhesive)IBA 11/2020
1	Retinaldehyde (Retinal)IBA 06/2020
1	Transcription Factors (Transcription Factor)IBA 06/2020

Therapy/Procedure

11	Therapeutics 01/2021 - 09/2014
4	Drug Therapy (Chemotherapy) 01/2021 - 10/2014
3	Precision Medicine 01/2022 - 01/2019
2	Magnetic Field Therapy 01/2022 - 01/2021
1	Sutures (Suture) 11/2020
1	Transplantation 11/2020